Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug helped patients achieve clear or almost clear ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch reduction in patients treated with roflumilast foam, 0.3%. Findings indicated ...

Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily ...

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin ...

The researchers reviewed information from 13 different studies and discovered that several types of drugs used to lower blood ...

Immunodermatology Disease Area Lead, Johnson & Johnson Innovative Medicine. "These new findings build upon the impressive scalp psoriasis results seen in ICONIC-LEAD and strengthen the breadth of ...